These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 19424992)

  • 1. Analysing risk attitudes to time.
    Oliver A; Cookson R
    Health Econ; 2010 Jun; 19(6):644-55. PubMed ID: 19424992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testing the internal consistency of the lottery equivalents method using health outcomes.
    Oliver A
    Health Econ; 2005 Feb; 14(2):149-59. PubMed ID: 15386678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preferences for 'life-saving' programmes: small for all or gambling for the prize?
    Gyrd-Hansen D; Kristiansen IS
    Health Econ; 2008 Jun; 17(6):709-20. PubMed ID: 17990283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamoxifen for breast cancer risk reduction: impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis.
    Melnikow J; Birch S; Slee C; McCarthy TJ; Helms LJ; Kuppermann M
    Med Care; 2008 Sep; 46(9):946-53. PubMed ID: 18725849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preferences for health outcomes and cost-utility analysis.
    Torrance GW
    Am J Manag Care; 1997 May; 3 Suppl():S8-20. PubMed ID: 10180342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the influence of gestalt-type characteristics on preferences over lifetime health profiles.
    Oliver A
    Med Decis Making; 2008; 28(5):723-31. PubMed ID: 18378938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The construction of standard gamble utilities.
    van Osch SM; Stiggelbout AM
    Health Econ; 2008 Jan; 17(1):31-40. PubMed ID: 17410521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [QALYS or not QALYS: that is the question?].
    Moatti JP; Auquier P; Le Coroller AG; Macquart-Moulin G
    Rev Epidemiol Sante Publique; 1995 Dec; 43(6):573-83. PubMed ID: 8552855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Willingness to pay per quality-adjusted life year in a study of knee osteoarthritis.
    Byrne MM; O'malley K; Suarez-Almazor ME
    Med Decis Making; 2005; 25(6):655-66. PubMed ID: 16282216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new explanation for the difference between time trade-off utilities and standard gamble utilities.
    Bleichrodt H
    Health Econ; 2002 Jul; 11(5):447-56. PubMed ID: 12112493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing the internal consistency of the standard gamble in 'success' and 'failure' frames.
    Oliver A
    Soc Sci Med; 2004 Jun; 58(11):2219-29. PubMed ID: 15047079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biases from omitted risk effects in standard gamble utilities.
    Pope R
    J Health Econ; 2004 Jul; 23(4):695-735. PubMed ID: 15587695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study on health economics regarding the screening of gastric cancer in Zhuanghe high risk area].
    Pan S; He QC; Zhou BS; Yuan Y
    Zhonghua Liu Xing Bing Xue Za Zhi; 2005 Oct; 26(10):757-60. PubMed ID: 16536299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm?
    Pickard AS; Wang Z; Walton SM; Lee TA
    Health Qual Life Outcomes; 2005 Mar; 3():11. PubMed ID: 15748287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?
    Braithwaite RS; Meltzer DO; King JT; Leslie D; Roberts MS
    Med Care; 2008 Apr; 46(4):349-56. PubMed ID: 18362813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value-based medicine comparative effectiveness and cost-effectiveness of penetrating keratoplasty for keratoconus.
    Roe RH; Lass JH; Brown GC; Brown MM
    Cornea; 2008 Oct; 27(9):1001-7. PubMed ID: 18812762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correcting biases in standard gamble and time tradeoff utilities.
    van Osch SM; Wakker PP; van den Hout WB; Stiggelbout AM
    Med Decis Making; 2004; 24(5):511-7. PubMed ID: 15359000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.